|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Considering cardiovascular diseases there is a number of genes involved in lipid metabolism (apolipoproteins, lipoprotein receptors, lipolytic enzymes), thrombosis/hemostasis (platelet receptors, pro- and anticoagulant proteins, fibrinogen, PAI's), hypertension (angiotensin converting enzyme, angiotensinogen) glucose metabolism (glucose transporters, enzymes) and obesity (hormones, receptors), that are interesting candidates for sophisticated genetic risk assessment.
|
9654602 |
1998 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
In conclusion, the results indicated that the I/D polymorphism of the ACE gene was not related to plasma PAI-1 levels in a Chinese population with hypertension.
|
9524054 |
1998 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Multivariate logistic regression analysis showed that PAI-1 4G/4G (P = 0.01) and the prevalence of hypertension (P < 0.0001) are independent risk factors of development of type 2 diabetic nephropathy.
|
10652041 |
2000 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Furthermore, increased plasma PAI-1 levels are associated with dyslipidemia, hyperinsulinemia and hypertension.
|
10867719 |
2000 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We found no associations between ACE I/D genotypes and plasma PAI-1 antigen concentrations in a subset of participants without major CHD risk factors (hypertension, hypercholesterolemia, overweight, smoking, diabetes) or in a small sample of African-Americans.
|
10997795 |
2000 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
The following parameters were evaluated in 104 patients with previously untreated hypertension: plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) antigen, fibrinogen, D-dimer, and von Willebrand factor (vWF).
|
11054622 |
2000 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
At multivariate analysis, only hyperhomocysteinemia (OR 11, 95% CI 3.6-36.2; p < 0.0001) and elevated PAI-1 levels (OR 8.9, 95% CI 3.5-41.3; p < 0.01), in addition to hypertension (OR 40.5, 95% CI 8.6-188.8; p < 0.00001) and hypercholesterolemia (OR 3.1, 95% CI 1.6-20.5; p < 0.05), were independent risk factors for CRVO.
|
11583306 |
2001 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aims of this study were to observe associations of the genetic polymorphism for PAI-1 and t-PA with hypertension and atherothrombotic stroke, and to elucidate whether impaired fibrinolytic activity in atherothrombotic stroke was related to atherothrombosis per se or to other risk factors such as hypertension.
|
11385207 |
2001 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
In 38 normotensive subjects with a family history of hypertension (relatives) and in 46 sex, age and body mass index matched controls with no family history of hypertension, tissue-type plasminogen activator (t-PA), plasminogen activator-inhibitor (PAI-1), D-dimer (DD) and prothrombin fragment 1+2 (F1+2) were evaluated.
|
11317134 |
2001 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 activity in Chinese patients with and without hypertension.
|
12670745 |
2003 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The present study showed that the 4G/4G genotype was associated with elevated plasma PAI-1 activity in Chinese patients with and without hypertension.
|
12670745 |
2003 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
LHGDN |
We therefore, prospectively studied the association of PAI-1 with early target organ damage in patients with arterial hypertension has not been clearly established.
|
12597520 |
2003 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension.
|
15194475 |
2004 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The present study showed a positive association of the IL-6 GG genotype with hypertension and with elevated plasma PAI-1 level in normotensive individuals in a Chinese population in Taiwan.
|
15831362 |
2005 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The present study showed a positive association of the IL-6 GG genotype with hypertension and with elevated plasma PAI-1 level in normotensive individuals in a Chinese population in Taiwan.
|
15831362 |
2005 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In conclusion, no association was found between M235T polymorphism and insulin resistance or PAI-1 levels, but results indicate relationship between I/D polymorphism of the ACE gene and plasma PAI-1 levels in the early stage of hypertension.
|
16981142 |
2006 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
|
Hypertensive disease
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Patients with metabolic syndrome were characterized with increased body mass index (BMI), waist circumference, and HOMA-IR and HOMA-beta levels, and all had increased blood pressure and triglyceride levels, low high-density lipoprotein cholesterol levels, increased PAI-1 levels and reduced antioxidative defense levels.
|
17848118 |
2007 |
|
Hypertensive disease
|
0.600 |
Therapeutic
|
group |
RGD |
Thiamine attenuates the hypertension and metabolic abnormalities in CD36-defective SHR: uncoupling of glucose oxidation from cellular entry accompanied with enhanced protein O-GlcNAcylation in CD36 deficiency.
|
16645728 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The T94G genotypes and plasma levels of adiponectin, and PAI-1 were determined in 568 Chinese patients, 212 with and 356 without hypertension, to study the possible associations of T94G genotype, plasma adiponectin, PAI-1 and blood pressure.
|
16741355 |
2007 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
The 4G/4G PAI-1 genotype was significantly associated with a high prevalence of arterial hypertension.
|
17351368 |
2007 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
We compared concentrations of 4 different biomarkers (urinary albumin:creatinine ratio, circulating C-reactive protein, aldosterone:renin ratio, and plasminogen activator inhibitor-1) in nonhypertensive Framingham offspring study participants with none (n=233), 1 (n=474), or both (n=322) parents with hypertension.
|
18574071 |
2008 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
BEFREE |
Post-phlebotomy, PRA and PAI-1 responses were more dramatic, but the NO response less in normotensive subjects having a parental history of hypertension, suggesting that these changes may represent familial, possibly genetic influences before overt hypertension occurs.
|
19154322 |
2008 |
|
Hypertensive disease
|
0.600 |
Biomarker
|
group |
CTD_human |
Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats.
|
21051829 |
2010 |